Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer

JCI Insight(2021)10.1172/jci.insight.146827Source: DataRank Database

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer is a research paper published in JCI Insight (2021). On theSindex it has a DataRank of 1.5. It has been cited 58 times, with 41 citing works in its 1-hop citation network.

N/A

1.5DataRank · unranked

Scored on demand from live citation data

Open Access58 citations · 41 citing works in its network

Download PDF

Cite:

Linked data & code

geo doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)Impact (FWCI 5.49)OA: goldTopics (91)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 41%Citation Network 59%

Base Score Contribution

0.612

From this paper's citation signal

Citation Network Contribution

0.894

From 33 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 41 citers.

Androgen receptor‐neuroendocrine double‐negative tumor with squamous differentiation arising from treatment‐refractory metastatic castration‐resistant prostate cancer
IJU Case Reports20215 citations7 referencesContributes 0.256
Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer
International Journal of Molecular Sciences202347 citations34 referencesContributes 0.114
ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer
Free Radical Biology and Medicine202329 citations49 referencesContributes 0.069
Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer
Pathology & Oncology Research202110 citations44 referencesContributes 0.054
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology
Nature Communications202172 citations80 referencesContributes 0.054

Authors (21)

Yezi Zhu,Ilsa M. Coleman ORCID,Susan L. Dalrymple ORCID,Lizamma Antony,Radhika A. Patel ORCID

Live enrichment

PubMed:33724955 PMC:PMC8119192 OpenAlex:https://openalex.org/W3138616138

Movember Foundation

Grant: na

Prostate Cancer Foundation

Grant: YIA

Prostate Cancer Foundation

Grant: Challenge Award

U.S. Department of Defense

Grant: W81XWH<2010>16<2010>1<2010>0410,W81XWH-18-1-0348,W81XWH-18-1-0347,W81XWH-17-1-0415,W81XWH<2010>17<2010>1<2010>0528,W81XWH-20-1-0111,W81XWH-10-2-0045,W82XWH-10-2-0056

NIH

Grant: P50 CA058236,P50 CA097186,R01 CA255259,R01 CA185297,P01CA163227,R01 CA234715,P30 CA006973

NIH

Grant: R01 CA255259

NCI NIH HHS

Grant: P50 CA097186

U.S. Department of Defense

Grant: W81XWH<2010>16<2010>1<2010>0410,W81XWH-18-1-0348,W81XWH-18-1-0347,W81XWH-17-1-0415,W81XWH<2010>17<2010>1<2010>0528,W81XWH-20-1-0111,W81XWH-10-2-0045,W82XWH-10-2-0056

NCI NIH HHS

Grant: P01 CA163227

NCI NIH HHS

Grant: P30 CA006973

NCI NIH HHS

Grant: R01 CA185297

NCI NIH HHS

Grant: R01 CA234715

NCI NIH HHS

Grant: P30 CA015704

NCI NIH HHS

Grant: P50 CA058236

National Institutes of Health

Grant: 5R01CA255259-05

A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression

National Institutes of Health

Grant: 6R01CA234715-03

Defining and Targeting Lineage Transition Programs Operative in AR Pathway Independent Prostate Cancer

National Institutes of Health

Grant: 5P50CA097186-13

Clinical Development of Therapeutic Strategies Targeting Damage Responses in the Prostate Tumor Microenvironment

National Institutes of Health

Grant: 3P30CA015704-42S2

Cancer Center Support Grant

National Institutes of Health

Grant: 3P50CA058236-02S1

SPECIALIZED PGM OF RESEARCH EXCELLENCE/PROSTATE CANCER

National Institutes of Health

Grant: 5R01CA185297-02

The aberrant androgen receptor underlies abiraterone/enzalutamide resistance

National Institutes of Health

Grant: 3P30CA006973-53S2

Regional Oncology Research Center

National Institutes of Health

Grant: 5P01CA163227-09

Androgen Receptor Action in Castration Resistant Prostate Cancer

FWCI

5.49

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1172/jci.insight.146827

publisherhttps://doi.org/10.1172/jci.insight.146827

publisherhttps://insight.jci.org/articles/view/146827/files/pdf

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33724955

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8119192

Fields of Study

Prostate Cancer Treatment and ResearchEstrogen and related hormone effectsRadiopharmaceutical Chemistry and Applications03 medical and health sciences0302 clinical medicineAbiraterone AcetateAnimalsAntineoplastic AgentsBenzamidesCarcinoma, NeuroendocrineCell Transformation, NeoplasticDrug Resistance, NeoplasmEnhancer of Zeste Homolog 2 ProteinMaleMiceNeoplasm TransplantationNitrilesPTEN PhosphohydrolasePhenylthiohydantoinProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRetinoblastoma Binding ProteinsSOXB1 Transcription FactorsThiohydantoinsTumor Suppressor Protein p53Ubiquitin-Protein Ligases

MeSH Terms

Abiraterone AcetateEnhancer of Zeste Homolog 2 ProteinAnimalsAntineoplastic AgentsBenzamidesCell Transformation, NeoplasticMaleNeoplasm TransplantationNitrilesPhenylthiohydantoinReceptors, AndrogenThiohydantoinsTumor Suppressor Protein p53Carcinoma, NeuroendocrineDrug Resistance, NeoplasmUbiquitin-Protein LigasesPTEN PhosphohydrolaseMiceSOXB1 Transcription FactorsRetinoblastoma Binding ProteinsProstatic Neoplasms, Castration-Resistant

Keywords

Androgen receptorProstate cancerPTENCancer researchEnzalutamidePhenotypeNeuroendocrine differentiationBiologyEZH2AndrogenSOX2CancerEpigeneticsGeneticsEndocrinologySignal transductionPI3K/AKT/mTOR pathwayTranscription factorGeneHormoneOncologyMaleAbiraterone AcetateAntineoplastic AgentsMiceNitrilesPhenylthiohydantoinAnimalsEnhancer of Zeste Homolog 2 ProteinSOXB1 Transcription FactorsRPTEN PhosphohydrolaseCarcinoma, NeuroendocrineProstatic Neoplasms, Castration-ResistantRetinoblastoma Binding ProteinsCell Transformation, NeoplasticThiohydantoinsDrug Resistance, NeoplasmReceptors, AndrogenBenzamidesMedicineTumor Suppressor Protein p53Neoplasm TransplantationResearch Article

Sustainable Development Goals

SDG 3: 3. Good health